BioSpace News Archive

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update to its intellectual property (“IP”) portfolio.

Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI) plans to announce its fourth quarter and full year 2022 financial and operating results after the market closes on Wednesday, February 22, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Cue Biopharma, Inc. (Nasdaq: CUE) announced today that its President and Chief Scientific Officer, Anish Suri, Ph.D., will participate in two scientific conferences this February, the Immuno-Oncology 360o Summit, taking place February 7-10 in New York, NY, and the Federation of American Societies for Experimental Biology (FASEB) Catalyst Conference.

Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present an overview of the company at the Guggenheim Healthcare Talks Oncology Conference in New York, NY.

Fortive Reports Strong Fourth Quarter and Full Year 2022 Results; Introduces First Quarter and Full Year 2023 Outlook.

Miromatrix Medical Inc. (NASDAQ: MIRO) and Baxter International Inc. (NYSE:BAX) today announced a collaborative research agreement to help support additional treatment options for patients with acute liver failure (ALF) in need of organ support therapies.

Daré Bioscience, Inc. today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in the following February conferences.

Cybrexa Therapeutics announced the appointments of Laurie Kenvin as Vice President of Clinical Operations and Nick Saccomano, Ph.D., to the Company’s Scientific Advisory Board.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today provided an update on the Twirla® post-marketing studies and status of its ongoing evaluation of the Company’s pipeline.

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Quan A. Vu as Chief Business Officer, responsible for securing new business development partnerships, including in/out licensing opportunities, across the Company’s pipeline.